

**NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED**

**INTERIM FINANCIAL STATEMENTS**

**MARCH 31, 2023**

518/3 อาคารเมเนียเซ็นเตอร์ นอธ ชั้น 7  
ถนนเพลินจิต แขวงลุมพินี  
เขตปทุมวัน กรุงเทพฯ 10330  
โทร./โทรสาร 0-2255-2518  
0-2250-0634  
0-2254-8387  
โทรสาร อัดโนมิตี 0-2253-8730  
อีเมล virach5183@yahoo.com  
เว็บไซต์ http://www.vaaudit.com

V & A

บริษัท สำนักงาน ดร.วิรัช แอนด์ แอสโซซิเอทส์ จำกัด  
DR.VIRACH & ASSOCIATES OFFICE CO., LTD.  
CERTIFIED PUBLIC ACCOUNTANTS  
สำนักงานใหญ่ เลขประจำตัวผู้เสียภาษี 0105556000751

518/3 Maneeya Center North Building  
7th Floor, Ploenchit Road, Lumpinee District  
Khet Patumwan, Bangkok 10330  
Tel./Fax 66 (0) 2255-2518  
2250-0634  
2254-8387  
Auto Fax 66 (0) 2253-8730  
Email virach5183@yahoo.com  
Website http://www.vaaudit.com

## INDEPENDENT AUDITOR'S REPORT ON REVIEW OF FINANCIAL INFORMATION

To : The Shareholders and The Board of Directors of  
Nonthavej Hospital Public Company Limited


I have reviewed the accompanying statements of financial position of Nonthavej Hospital Public Company Limited as at March 31, 2023, the related statements of comprehensive income, changes in shareholders' equity and cash flows for the three-month period then ended, and the condensed notes to the financial statements. Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 : Interim Financial Reporting. My responsibility is to express a conclusion on this interim financial information based on my review.

### *Scope of review*

I conducted my review in accordance with the Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

### *Conclusion*

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 : Interim Financial Reporting.



(Ms. Ratchneekon Vijaksilp)

Certified Public Accountant Registration No. 5801

Dr. Virach & Associates Office Co., Ltd.

Bangkok : May 10, 2023

**NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED**

**STATEMENTS OF FINANCIAL POSITION**

**AS AT MARCH 31, 2023**

**ASSETS**

|  |       | THOUSAND BAHT           |                            |
|--|-------|-------------------------|----------------------------|
|  |       | As at March 31,<br>2023 | As at December 31,<br>2022 |
|  |       | UNAUDITED<br>REVIEWED   | AUDITED                    |
|  | Notes |                         |                            |
| <b>Current Assets</b>  |       |                         |                            |
| Cash and cash equivalents                                    | 4     | 1,116,667               | 975,946                    |
| Trade receivable and other current receivables               | 5     | 176,125                 | 212,871                    |
| Inventories  |       | 53,873                  | 61,893                     |
| <b>Other current financial assets</b>                        |       |                         |                            |
| Investments in Open-ended Fund                               | 6.1   | 36                      | 38                         |
| Marketable securities  | 6.2   | 998                     | 1,043                      |
| Total other current financial assets                         |       | 1,034                   | 1,081                      |
| <b>Current portion of other non-current financial assets</b> |       |                         |                            |
| Other investment   | 7.2   | -                       | 100,000                    |
| <b>Other current assets</b>                                  |       |                         |                            |
| Prepaid expenses   |       | 19,485                  | 22,912                     |
| Other current assets   |       | 4,341                   | 3,267                      |
| Total other current assets                                   |       | 23,826                  | 26,179                     |
| <b>Total Current Assets</b>                                  |       | 1,371,525               | 1,377,970                  |
| <b>Non-current Assets</b>                                    |       |                         |                            |
| <b>Other non-current financial assets</b>                    |       |                         |                            |
| Marketable securities  | 7.1   | 15,226                  | 15,377                     |
| Other investment   | 7.2   | 200,000                 | 100,000                    |
| Total other non-current financial assets                     |       | 215,226                 | 115,377                    |
| Property, plant and equipment                                |       | 1,205,603               | 1,228,914                  |
| Intangible assets  |       | 25,085                  | 26,702                     |
| Deferred tax assets  | 10    | 16,504                  | 15,852                     |
| Other non-current assets                                     |       | 6,341                   | 7,404                      |
| <b>Total Non-current Assets</b>                              |       | 1,468,759               | 1,394,249                  |
| <b>TOTAL ASSETS</b>  |       | 2,840,284               | 2,772,219                  |

DY

Notes to the interim financial statements form an integral part of these statements.

**NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED**

**STATEMENTS OF FINANCIAL POSITION**

**AS AT MARCH 31, 2023**

**LIABILITIES AND SHAREHOLDERS' EQUITY**

|   |       | THOUSAND BAHT           |                            |
|---|-------|-------------------------|----------------------------|
|   |       | As at March 31,<br>2023 | As at December 31,<br>2022 |
|   |       | UNAUDITED<br>REVIEWED   | AUDITED                    |
|   | Notes |                         |                            |
| <b>Current Liabilities</b>                        |       |                         |                            |
| Trade and other current payables                  | 8     | 175,514                 | 209,333                    |
| Assets acquisition payable                        |       | 12,022                  | 11,164                     |
| Dividend payable                                  | 9     | 180,800                 | -                          |
| Accrued corporate income tax                      |       | 55,621                  | 40,314                     |
| Other current liabilities                         |       | 7,619                   | 8,625                      |
| <b>Total Current Liabilities</b>                  |       | <b>431,576</b>          | <b>269,436</b>             |
| <b>Non-current Liabilities</b>                    |       |                         |                            |
| Provision for long-term employee benefits         |       | 74,670                  | 71,571                     |
| <b>Total Non-current Liabilities</b>              |       | <b>74,670</b>           | <b>71,571</b>              |
| <b>TOTAL LIABILITIES</b>                          |       | <b>506,246</b>          | <b>341,007</b>             |
| <b>Shareholders' Equity</b>                       |       |                         |                            |
| <b>Share capital</b>                              |       |                         |                            |
| <b>Authorized share capital</b>                   |       |                         |                            |
| 160,000,000 common stocks of Baht 1 par value     |       | 160,000                 | 160,000                    |
| <b>Issued and paid-up share capital</b>           |       |                         |                            |
| 160,000,000 common stocks at Baht 1 each          |       | 160,000                 | 160,000                    |
| <b>Additional paid-in capital</b>                 |       |                         |                            |
| Premium on common stocks                          |       | 172,000                 | 172,000                    |
| <b>Retained earnings</b>                          |       |                         |                            |
| <b>Appropriated</b>                               |       |                         |                            |
| Legal reserve                                     |       | 16,000                  | 16,000                     |
| <b>Unappropriated</b>                             |       |                         |                            |
|   |       | 1,974,035               | 2,071,088                  |
| Other components of shareholders' equity          |       | 12,003                  | 12,124                     |
| <b>Total Shareholders' Equity</b>                 |       | <b>2,334,038</b>        | <b>2,431,212</b>           |
| <b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b> |       | <b>2,840,284</b>        | <b>2,772,219</b>           |

RSY

Notes to the interim financial statements form an integral part of these statements.

UNAUDITED

REVIEWED

**NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED**  
**STATEMENTS OF COMPREHENSIVE INCOME**  
**FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2023**

|  | Notes | THOUSAND BAHT           |          |
|--|-------|-------------------------|----------|
|  |       | EXCEPT EARNINGS PER     |          |
|  |       | SHARE PRESENTED IN BAHT |          |
|  |       | 2023                    | 2022     |
| <b>REVENUES</b>  |       |                         |          |
| Revenues from medical treatment  |       | 568,802                 | 489,339  |
| Other income   |       | 9,034                   | 4,881    |
| Total Revenues   |       | 577,836                 | 494,220  |
| <b>EXPENSES</b>  |       |                         |          |
| Cost of medical treatment  |       | 400,394                 | 364,342  |
| Selling expenses   |       | 1,364                   | 972      |
| Administrative expenses  |       | 72,597                  | 65,853   |
| Directors' remuneration  | 9     | 1,097                   | 665      |
| Total Expenses   |       | 475,452                 | 431,832  |
| Profit from operating activities   |       | 102,384                 | 62,388   |
| Finance income   |       | 2,092                   | 431      |
| Reversal (allowance for expected credit loss)  |       | 36                      | (61)     |
| Unrealized loss on open-ended funds  |       | (2)                     | -        |
| Unrealized loss on marketable securities   |       | (45)                    | (85)     |
| Profit before Income Tax Expenses  |       | 104,465                 | 62,673   |
| Income Tax Expenses  | 10    | (20,718)                | (12,420) |
| Profit for the periods   |       | 83,747                  | 50,253   |
| <b>Other Comprehensive Income (Loss) :-</b>  |       |                         |          |
| Other comprehensive income not to be reclassified<br>to profit or loss in subsequent periods |       |                         |          |
| Gain (loss) on changes in value of marketable securities                                     |       |                         |          |
| Gain (loss) recognized in other comprehensive income   |       | (151)                   | 677      |
| Income tax on net change from the remeasuring<br>of marketable securities                    |       | 30                      | (135)    |
| Other comprehensive income (loss) for the periods - net of tax                               |       | (121)                   | 542      |
| Total comprehensive income for the periods   |       | 83,626                  | 50,795   |
| <b>Earnings Per Share (Baht)</b>   |       |                         |          |
| Basic Earnings Per Share   |       | 0.52                    | 0.31     |
| The number of 160,000,000 common stocks used in computation.                                 |       |                         | PSY      |

Notes to the interim financial statements form an integral part of these statements.

**NONHAVEJ HOSPITAL PUBLIC COMPANY LIMITED**  
**STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY**  
**FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2023**

|   | THOUSAND BAHT                          |                                |                   |               |                |  | Total<br>shareholders'<br>equity |
|---|--|--------------------------------|-------------------|---------------|----------------|--|----------------------------------|
|   | Issued and<br>paid-up<br>share capital | Premium on<br>common<br>stocks | Retained earnings | Legal reserve | Unappropriated | Other components of<br>shareholders' equity<br>Other comprehensive<br>income (loss)<br>Marketable securities |                                  |
| <b>Year 2023</b>                          |  |                                |                   |               |                |  |                                  |
| Balances as at January 1, 2023            | 160,000                                | 172,000                        | 16,000            | 2,071,088     |                | 12,124   | 2,431,212                        |
| Total comprehensive income for the period | -                                      | -                              | -                 | 83,747        |                | (121)  | 83,626                           |
| Dividend payment                          | -                                      | -                              | -                 | (180,800)     |                | -  | (180,800)                        |
| Balances as at March 31, 2023             | 160,000                                | 172,000                        | 16,000            | 1,974,035     |                | 12,003   | 2,334,038                        |
| <b>Year 2022</b>                          |  |                                |                   |               |                |  |                                  |
| Balances as at January 1, 2022            | 160,000                                | 172,000                        | 16,000            | 1,866,525     |                | 8,924  | 2,223,449                        |
| Total comprehensive income for the period | -                                      | -                              | -                 | 50,253        |                | 542  | 50,795                           |
| Dividend payment                          | -                                      | -                              | -                 | (96,000)      |                | -  | (96,000)                         |
| Balances as at March 31, 2022             | 160,000                                | 172,000                        | 16,000            | 1,820,778     |                | 9,466  | 2,178,244                        |

BY

Notes to the interim financial statements form an integral part of these statements.

UNAUDITED

REVIEWED

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF CASH FLOWS

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2023

|   | THOUSAND BAHT |          |
|---|---------------|----------|
|   | 2023          | 2022     |
| CASH FLOWS FROM OPERATING ACTIVITIES :  |               |          |
| PROFIT FOR THE PERIODS  | 83,747        | 50,253   |
| ADJUSTMENTS TO RECONCILE PROFIT FOR THE PERIODS<br>TO NET CASH PROVIDED FROM (USED IN) OPERATION :- |               |          |
| Income tax expenses   | 20,718        | 12,420   |
| Depreciation  | 41,295        | 41,863   |
| Amortization of deferred expenses   | 1,017         | 897      |
| Amortization of computer softwares  | 1,971         | 1,730    |
| Unrealized loss on open-ended funds   | 2             | -        |
| Unrealized loss on marketable securities  | 45            | 85       |
| Gain on disposal of equipment   | (58)          | (53)     |
| Loss on unused assets   | -             | 68       |
| Bad debts   | -             | 30       |
| (Reversal) allowance for expected credit loss   | (36)          | 61       |
| Dividend income   | (191)         | (88)     |
| Financial income  | (2,092)       | (431)    |
| Long-term employee benefits expenses  | 3,099         | 2,865    |
| PROFIT FROM OPERATION BEFORE CHANGE IN<br>OPERATING ASSETS AND LIABILITIES ITEMS                    | 149,517       | 109,700  |
| (INCREASE) DECREASE IN OPERATING ASSETS ITEMS   |               |          |
| Trade and other current receivables   | 36,782        | 3,233    |
| Inventories   | 8,020         | 5,795    |
| Other current assets  | 3,752         | 4,205    |
| Other non-current assets  | 46            | (448)    |
| DECREASE IN OPERATING LIABILITIES ITEMS   |               |          |
| Trade and other current payables  | (34,299)      | (18,532) |
| Assets acquisition payable  | (1,974)       | (28,321) |
| Other current liabilities   | (1,006)       | (1,205)  |
| Cash received from operation  | 160,838       | 74,427   |
| Interest income   | 800           | -        |
| Income tax paid   | (6,033)       | (4,218)  |
| NET CASH PROVIDED FROM OPERATING ACTIVITIES   | 155,605       | 70,209   |

Notes to the interim financial statements form an integral part of these statements.

Ry

UNAUDITED

REVIEWED

**NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED**  
**STATEMENTS OF CASH FLOWS (CONTINUED)**  
**FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2023**

|   | THOUSAND BAHT    |                 |
|---|------------------|-----------------|
|   | 2023             | 2022            |
| CASH FLOWS FROM INVESTING ACTIVITIES                            |                  |                 |
| Increase in plant and equipment                                 | (14,881)         | (35,557)        |
| Proceeds from disposal of equipment                             | 267              | 97              |
| Increase in intangible assets                                   | (354)            | (816)           |
| Proceeds from dividend income                                   | 84               | 56              |
| NET CASH USED IN INVESTING ACTIVITIES                           | <u>(14,884)</u>  | <u>(36,220)</u> |
| NET INCREASE IN CASH AND CASH EQUIVALENTS                       | 140,721          | 33,989          |
| CASH AND CASH EQUIVALENTS AS AT JANUARY 1,                      | 975,946          | 793,620         |
| CASH AND CASH EQUIVALENTS AS AT MARCH 31,                       | <u>1,116,667</u> | <u>827,609</u>  |
| ADDITIONAL DISCLOSURE ITEMS TO CASH FLOWS STATEMENTS            |                  |                 |
| Non-cash flows items comprise :                                 |                  |                 |
| Unrealized gain (loss) on marketable securities                 | (151)            | 677             |
| Increase in plant and equipment from assets acquisition payable | 2,832            | 5,401           |
| Increase in intangible assets from transferring fixed assets    | -                | 256             |
| Increase in equipment from retention                            | 480              | 1,036           |
| Dividend payable  | 180,800          | 96,000          |
| Accrued dividend income   | 107              | 32              |

PR

Notes to the interim financial statements form an integral part of these statements.



**NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED**

**NOTES TO THE INTERIM FINANCIAL STATEMENTS**

**MARCH 31, 2023**

**1. GENERAL INFORMATION**

|     |                  |  |
|-----|------------------|--|
| 1.1 | Company status   | A juristic person established under Thai law and listed on the Stock Exchange of Thailand. |
| 1.2 | Company location | 432, Ngamvongwan Road, Tambol Bangkhen, Amphur Muangnonthaburi, Nonthaburi, Thailand.      |
|     | Branch           | 530, Rattanathibeth Road, Tambol Bangkrasor, Amphur Muangnonthaburi, Nonthaburi, Thailand. |
| 1.3 | Type of business | Hospital   |

**2. BASIS FOR PREPARATION OF INTERIM FINANCIAL STATEMENTS**

2.1 The interim financial statements are prepared on a condensed basis in accordance with Thai Accounting Standard No.34 : Interim Financial Reporting issued by the Federation of Accounting Professions and the Notification of the Office of Securities and Exchange Commission. These interim financial statements should be read in conjunction with the financial statements for the year ended December 31, 2022.

2.2 Accounting standards that became effective in the current accounting period

The Company has adopted the revised financial reporting standards, which are effective for fiscal years beginning on or after January 1, 2023. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and, for some standards, providing temporary reliefs or temporary exemptions for users.

These financial reporting standards do not have any significant impact on the financial statements of the Company.

2.3 These interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies.

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The accounting policies and method of computation applied in these interim financial statements are consistent with those applied in the financial statements for the year ended December 31, 2022.

**4. CASH AND CASH EQUIVALENTS**

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS   | As at March 31, 2023 | As at December 31, 2022 |
|---------------|----------------------|-------------------------|
| Cash          | 1,380                | 1,897                   |
| Bank deposits | 1,115,287            | 974,049                 |
| Total         | 1,116,667            | 975,946                 |

**5. TRADE AND OTHER CURRENT RECEIVABLES**

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS  | As at March 31, 2023 | As at December 31, 2022 |
|--|----------------------|-------------------------|
| The trade accounts receivable are classified by outstanding balances of aging as follows : |                      |                         |
| Current  | 164,472              | 200,605                 |
| Overdue within 3 months  | 8,637                | 8,664                   |
| Over 3 - 6 months  | 2,815                | 3,422                   |
| Over 6 - 12 months   | 7,965                | 11,447                  |
| Over 12 months   | 14,071               | 10,604                  |
| Total  | 197,960              | 234,742                 |
| Allowance for expected credit loss   | (21,835)             | (21,871)                |
| Trade accounts receivable-net  | 176,125              | 212,871                 |
| Total trade and other current receivables  | 176,125              | 212,871                 |

## 6. OTHER CURRENT FINANCIAL ASSETS

## 6.1 Open-ended Fund

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS                | As at March 31, 2023 |  | As at December 31, 2022 |  |
|----------------------------|----------------------|--|-------------------------|--|
|                            |                      |  |                         |  |
| Open-ended Fund            | 47                   |  | 47                      |  |
| Valuation adjustment       | (11)                 |  | (9)                     |  |
| Open-ended Fund-Fair value | 36                   |  | 38                      |  |

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS  | For the three-month periods ended March 31, |      |
|--|---|------|
|  | 2023  | 2022 |
| Unrealized loss on investments in<br>Open-ended Fund | 2   | -    |

## 6.2 Marketable securities

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS                  | As at March 31, 2023 |  | As at December 31, 2022 |  |
|------------------------------|----------------------|--|-------------------------|--|
|                              |                      |  |                         |  |
| Acquisition cost             | 2,008                |  | 2,008                   |  |
| Valuation adjustment         | (1,010)              |  | (965)                   |  |
| Fair value at ending periods | 998                  |  | 1,043                   |  |

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS                              | For the three-month periods ended March 31, |      |
|--|---|------|
|  | 2023  | 2022 |
| Unrealized loss on marketable securities | 45  | 85   |

**7. OTHER-NON-CURRENT FINANCIAL ASSETS****7.1 Marketable securities**

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS                  | As at March 31, 2023 | As at December 31, 2022 |
|------------------------------|----------------------|-------------------------|
| Acquisition cost             | 222                  | 222                     |
| Valuation adjustment         | 15,004               | 15,155                  |
| Fair value at ending periods | 15,226               | 15,377                  |

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS  | For the three-month periods<br>ended March 31, |      |
|--|--|------|
|  | 2023   | 2022 |
| Gain (loss) on changes in value of marketable securities | (151)  | 677  |

**7.2 Other investment**

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS                            | As at March 31, 2023 | As at December 31, 2022 |
|--|----------------------|-------------------------|
| Savings lottery (due January 8, 2023)  | -                    | 100,000                 |
| Savings lottery (due October 3, 2024)  | 100,000              | 100,000                 |
| Savings lottery (due January 11, 2025) | 100,000              | -                       |
| Total                                  | 200,000              | 200,000                 |
| Current portion                        | -                    | (100,000)               |
| Total                                  | 200,000              | 100,000                 |

**8. TRADE AND OTHER CURRENT PAYABLES**

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS             | As at March 31, 2023 | As at December 31, 2022 |
|-------------------------|----------------------|-------------------------|
| Trade accounts payables | 47,249               | 62,941                  |
| Accrued expenses        | 27,841               | 33,152                  |
| Accrued doctors' fees   | 74,598               | 79,791                  |
| Others                  | 25,826               | 33,449                  |
| Total                   | 175,514              | 209,333                 |

## 9. DIVIDEND PAYMENT AND DIRECTOR'S REMUNERATION

On February 21, 2023, the Board of Directors' Meeting was held and has a resolution to pay dividend at Baht 1.13 per share to the shareholders of 160 million shares, totalling Baht 180.80 million. On April 21, 2023, the Ordinary General Shareholders' Meeting was held and approved a resolution to pay such proposed dividend, including directors' remuneration amounting to Baht 3.01 million, and annual meeting allowance as specified. By fixing the payment date for dividend on May 19, 2023.

On March 10, 2022, the Board of Directors' Meeting was held and has a resolution to pay dividend at Baht 0.60 per share to the shareholders of 160 million shares, totalling Baht 96 million. On April 22, 2022, the Ordinary General Shareholders' Meeting was held and approved a resolution to pay such proposed dividend, including directors' remuneration amounting to Baht 1.59 million, and annual meeting allowance as specified. By fixing the payment date for dividend on May 20, 2022.

## 10. INCOME TAXES

Corporate income tax of the Company for the three-month periods ended March 31, 2023 and 2022 are calculated from the accounting profits and adjusted with other revenues and some expenses which are exempted from income tax or being disallowable expenses in corporate income tax computation.

The Company income taxes are calculated at the rate of 20 percent.

Income tax expenses recognized in statements of comprehensive income consist:

(AMOUNT IN THOUSAND BAHT)

| FOR THE THREE-MONTH PERIODS ENDED MARCH 31,   | 2023   | 2022   |
|---|--------|--------|
| Corporate income tax for the periods  | 21,340 | 13,022 |
| Amortization and reversal of temporary differences<br>assets/liabilities on temporary differences | (622)  | (602)  |
| Income tax expenses   | 20,718 | 12,420 |

As at March 31, 2023 and December 31, 2022, the deferred tax assets/liabilities arose from the following temporary differences:

(AMOUNT IN THOUSAND BAHT)

| PARTICULARS  | As at March 31,<br>2023 | As at December 31,<br>2022 |
|--|-------------------------|----------------------------|
| <b>Temporary differences in the statements of comprehensive income</b> |                         |                            |
| Allowance for adjustment investment value in Open-ended Fund           | 11                      | 9                          |
| Allowance for adjustment in market securities                          |                         |                            |
| -other current financial assets  | 1,010                   | 965                        |
| Allowance for expected credit loss                                     | 21,835                  | 21,871                     |
| Provision for long-term employee benefits                              | 74,670                  | 71,571                     |
| Total  | 97,526                  | 94,416                     |
| <b>Temporary differences in other comprehensive income</b>             |                         |                            |
| <b>- Recognized in other components of shareholders' equity</b>        |                         |                            |
| Allowance for adjustment in market securities                          |                         |                            |
| -other non-current financial assets                                    | (15,004)                | (15,155)                   |
| Total  | 82,522                  | 79,261                     |
| <b>Deferred tax assets calculated from tax rate of 20%.</b>            | 16,504                  | 15,852                     |

## 11. FINANCIAL INFORMATION BY SEGMENT

The Company is engaged in the business of medical treatment in one geographical area, Thailand. Therefore, the financial information by segment is not shown in these financial statements.

**12. COMMITMENT**

12.1 As at March 31, 2023 and December 31, 2022, the Company has commitment from the issuance of bank guarantee as follow :

| PARTICULAR                                     | (AMOUNT IN THOUSAND BAHT) |                         |
|--|---------------------------|-------------------------|
|  | As at March 31, 2023      | As at December 31, 2022 |
| Letters of guarantee issued by commercial bank | 4,277                     | 4,277                   |

**12.2 Commitment under service agreement**

As at March 31, 2023, the Company has entered into service agreements which can be cancelled when the counter party has prior notice 30 to 60 days in advance the amount of Baht 11.17 million.

**12.3 Capital expenditure commitments**

As at March 31, 2023, the Company has capital expenditure commitments to pay a total of Baht 53.69 million in regarding to the improvement of system and construction project.

**13. FINANCIAL STATEMENTS APPROVAL**

These interim financial statements are duly approved by the Company's Board of Directors on May 10, 2023.